Arcutis (ARQT) director Lin granted 5,778 RSUs and 16,667 options

Rhea-AI Filing Summary

Arcutis Biotherapeutics director Sue-Jean Lin reported equity awards tied to board service. She received 5,778 Restricted Stock Units as of the company’s 2026 annual stockholder meeting, bringing her direct common stock holdings to 32,513 shares after the award.

Each RSU converts into one share of common stock upon vesting, which occurs on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting, subject to continued service. Settlement of the vested RSUs has been deferred under a prior deferral election.

Lin was also granted a stock option covering 16,667 shares of common stock at an exercise price of $21.23 per share. The option vests and becomes exercisable in full on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before the next annual meeting of stockholders, contingent on continued board service through that date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider LIN SUE-JEAN

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	16,667	$0.00	--
Grant/Award	Common Stock	5,778	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 16,667 shares (Direct, null); Common Stock — 32,513 shares (Direct, null)

Footnotes (1)

1. Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on October 26, 2025, maintained by the Company. The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.

Key Figures

RSUs granted: 5,778 units Shares held after award: 32,513 shares Stock options granted: 16,667 options +3 more

6 metrics

RSUs granted 5,778 units Equity award as non-employee director as of 2026 annual meeting

Shares held after award 32,513 shares Direct common stock holdings following RSU grant

Stock options granted 16,667 options New option award covering underlying common shares

Option exercise price $21.23 per share Strike price for 16,667-share stock option grant

Option expiration June 5, 2036 Expiration date of stock option if unexercised

RSU vesting trigger Earlier of June 5, 2026 or next annual meeting Time-based vesting condition for 5,778 RSUs

Key Terms

Restricted Stock Units ("RSUs"), Stock Option (right to buy), exercise price, vesting, +1 more

5 terms

Restricted Stock Units ("RSUs") financial

"Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (right to buy) financial

"Stock Option (right to buy) with underlying security title Common Stock"

exercise price financial

"conversion_or_exercise_price: "21.2300" for the stock option grant"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

RSU Deferral Election Form financial

"settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on October 26, 2025"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LIN SUE-JEAN

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CALIFORNIA 91361

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		A		5,778(1)	A	$0	32,513	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$21.23	06/05/2026		A		16,667		(2)	06/05/2036	Common Stock	16,667	$0	16,667	D

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on October 26, 2025, maintained by the Company.

2. The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.

Remarks:

	/s/ Latha Vairavan, as Attorney-in-Fact for Sue-Jean Lin	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Arcutis (ARQT) director Sue-Jean Lin report?

Sue-Jean Lin reported receiving 5,778 Restricted Stock Units and a stock option for 16,667 shares of Arcutis common stock. Both awards are tied to her service as a non-employee director and vest based on time and board service conditions.

How many Arcutis (ARQT) shares does Sue-Jean Lin hold after this Form 4?

After the reported equity award, Sue-Jean Lin holds 32,513 shares of Arcutis common stock directly. This figure includes the newly granted 5,778 Restricted Stock Units that convert into shares upon vesting, reflecting her updated equity position as a non-employee director.

What are the vesting terms of Sue-Jean Lin’s RSUs from Arcutis (ARQT)?

The 5,778 Restricted Stock Units vest in full on the earlier of the first anniversary of the June 5, 2026 grant date or immediately before Arcutis’s next annual stockholder meeting, provided Sue-Jean Lin continues serving as a director through that vesting date.

What are the key details of the Arcutis (ARQT) stock option granted to Sue-Jean Lin?

Sue-Jean Lin received a stock option for 16,667 underlying shares at a $21.23 exercise price. The option vests and becomes fully exercisable on the earlier of the first anniversary of June 5, 2026, or immediately before Arcutis’s next annual stockholder meeting, contingent on continued service.

How is settlement of Sue-Jean Lin’s Arcutis (ARQT) RSUs handled after vesting?

Upon vesting, each of Sue-Jean Lin’s 5,778 Restricted Stock Units entitles her to one Arcutis common share. However, settlement of these vested RSUs has been deferred according to an RSU Deferral Election Form she adopted on October 26, 2025.